)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Active Biotech
Active Biotech (ACTI) investor relations material
Active Biotech Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary7 May, 2026
Executive summary
Focused on advancing tasquinimod in myelofibrosis and business development for laquinimod in inflammatory eye disorders.
Achieved key milestones: US patent granted for tasquinimod, positive FDA feedback, and resumed patient enrollment in US myelofibrosis study.
Published preclinical data for tasquinimod in myelodysplastic neoplasms and LION study results for laquinimod.
Financial highlights
No net sales recorded in Q1 2026.
Operating loss was SEK 8.6M, a 23% improvement from SEK 11.2M in Q1 2025.
Research and development expenses decreased 29% year-over-year to SEK 5.8M.
Loss after tax was SEK 8.4M, compared to SEK 11.0M in Q1 2025.
Cash and cash equivalents at period end were SEK 53.3M, down from SEK 65.1M at year-end 2025.
Outlook and guidance
Ongoing proof-of-concept studies for tasquinimod in myelofibrosis in the US and Europe, with interim readouts expected late 2026 and efficacy results by end of 2027.
Laquinimod is phase II ready; partnering activities are ongoing to secure a commercial partner.
Available liquidity expected to fund operations through 2026 and 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Active Biotech
- Advancing immunomodulatory therapies in cancer and eye disorders with strong clinical and market momentum.ACTI
Company presentation23 Apr 2026 - Advancing immunomodulatory drugs in oncology and eye disorders with strong clinical momentum.ACTICompany presentation26 Mar 2026
- Clinical progress and strengthened finances position the company for key readouts in 2026–2027.ACTIQ4 202512 Feb 2026
- Late-stage immunomodulatory pipeline targets high-value cancer and eye disorder markets.ACTICompany Presentation6 Nov 2025
- Advanced clinical progress and SEK 70M rights issue, but going concern risk remains.ACTIQ3 20256 Nov 2025
- Clinical milestones achieved in Q2; liquidity sufficient for 2025, but more funding needed.ACTIQ2 202521 Aug 2025
- Clinical progress in myelofibrosis and uveitis, but urgent financing needs persist.ACTIQ3 202413 Jun 2025
- Q2 saw clinical progress and narrowed losses, but new funding is needed for continued operations.ACTIQ2 202413 Jun 2025
- Clinical pipeline advanced with positive laquinimod results and new tasquinimod studies; funding needs remain.ACTIQ1 20255 Jun 2025
Next Active Biotech earnings date
Q2 202620 Aug, 2026
Active Biotech
Next Active Biotech earnings date
Q2 202620 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage